Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.5K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Prospective noninterventional BLUE SKY study evaluating the efficacy of brolucizumab in treatment-naïve and previously treated patients with neovascular AMD].

Die Ophthalmologie·2022
Same author

[Real-life experiences with Brolucizumab in recalcitrant neovascular age-related macular degeneration].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2021
Same author

[IVOM quality assurance in Westfalen-Lippe : Structure of quality assurance and results of the pilot study Q-VERA].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2020
Same author

[Treatment adherence and effectiveness of anti-Vascular Endothelial Growth Faktor(VEGF) treatment of diabetic macular edema in the clinical routine : Comparison between cooperative and unicentric organization of treatment].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2019
Same author

[Pro re nata anti-VEGF treatment results for neovascular age-related macular degeneration in routine clinical treatment: comparison of single with triple injections].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2018
Same author

[Management of anticoagulants in ophthalmic surgery-a survey among ophthalmic surgeons in Germany].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2018

Related Experiment Video

Updated: Mar 17, 2026

Intravitreal Injections in the Ovine Eye
03:37

Intravitreal Injections in the Ovine Eye

Published on: July 5, 2022

4.3K

[Analysis of Anti-VEGF Intravitreal Injection Treatment in Clinical Practice].

J Bouws1, D Pauleikhoff2, K D Lemmen3

  • 1AMD-Netz, Münster.

Klinische Monatsblatter Fur Augenheilkunde
|August 2, 2016
PubMed
Summary

Intravitreal operative drugs (IVOM) for AMD patients require timely treatment. Streamlining appointment scheduling and treatment pathways can improve patient satisfaction and compliance.

More Related Videos

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

1.9K
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.6K

Related Experiment Videos

Last Updated: Mar 17, 2026

Intravitreal Injections in the Ovine Eye
03:37

Intravitreal Injections in the Ovine Eye

Published on: July 5, 2022

4.3K
Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

1.9K
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.6K

Area of Science:

  • Ophthalmology
  • Medical Practice Management

Background:

  • Age-related Macular Degeneration (AMD) frequently necessitates intravitreal operative drugs (IVOM).
  • Current treatment procedures for IVOM in ophthalmological settings were analyzed.
  • Data were collected from 42 facilities including private practices and university departments.

Purpose of the Study:

  • To evaluate the current structures, criteria, and time expenditure for IVOM administration in ophthalmology.
  • To identify potential areas for improving treatment efficiency and patient experience.

Main Methods:

  • A questionnaire was distributed to ophthalmological facilities.
  • Data collected included treatment structures, diagnostic criteria, and time spent on appointments and procedures.
  • Analysis focused on the patient journey from initial contact to follow-up care.

Main Results:

  • Initial appointments are typically scheduled within two weeks, with treatment commencing shortly after.
  • Follow-up appointments and retreatment decisions are guided by SD-OCT, vision, and funduscopy.
  • Variations exist in treatment timelines between practice types, with private practices potentially being faster than university departments.

Conclusions:

  • Reducing waiting times for IVOM appointments and treatment is crucial for patient satisfaction.
  • Inter-provider cooperation can shorten treatment pathways, benefiting both patients and ophthalmologists.
  • Standardized and efficient treatment pathways enhance patient care, satisfaction, and compliance.